Evidence map›Paper›PMID 24800810›Full record

Trial reportPloS one2014

Lower fetuin-A, retinol binding protein 4 and several metabolites after gastric bypass compared to sleeve gastrectomy in patients with type 2 diabetes.

Mia Jüllig, Shelley Yip, Aimin Xu, Greg Smith, Martin Middleditch, Michael Booth, Richard Babor, Grant Beban, Rinki Murphy

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 3 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Metabolomic signatures after bariatric surgery - a systematic review.Reviews in endocrine & metabolic disorders · 2022
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 3 countries.

Mia JülligMaurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand; School of Biological Sciences, University of Auckland, Auckland, New Zealand.
Shelley YipDepartment of Medicine, University of Auckland, Auckland, New Zealand.
Aimin XuDepartment of Medicine, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, Special Administrative Region, China.
Greg SmithDepartment of Pharmacology, University of New South Wales, Sydney, New South Wales, Australia.
Martin MiddleditchMaurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand; School of Biological Sciences, University of Auckland, Auckland, New Zealand.
Michael BoothDepartment of Surgery, North Shore Hospital, Auckland, New Zealand.
Richard BaborDepartment of Surgery, Middlemore Hospital, Auckland, New Zealand.
Grant BebanDepartment of Surgery, Auckland City Hospital, Auckland, New Zealand.
Rinki MurphyDepartment of Medicine, University of Auckland, Auckland, New Zealand.
Maurice Wilkins Centre · NZUniversity of Auckland · NZAuckland City Hospital · NZMiddlemore Hospital · NZNorth Shore Hospital · NZUniversity of Hong Kong · HKUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBypass of foregut secreted factors promoting insulin resistance is hypothesized to be one of the mechanisms by which resolution of type 2 diabetes (T2D) follows roux-en-y gastric bypass (GBP) surgery.

aimTo identify insulin resistance-associated proteins and metabolites which decrease more after GBP than after sleeve gastrectomy (SG) prior to diabetes remission.

methodsFasting plasma from 15 subjects with T2D undergoing GBP or SG was analyzed by proteomic and metabolomic methods 3 days before and 3 days after surgery. Subjects were matched for age, BMI, metformin therapy and glycemic control. Insulin resistance was calculated using homeostasis model assessment (HOMA-IR). For proteomics, samples were depleted of abundant plasma proteins, digested with trypsin and labeled with iTRAQ isobaric tags prior to liquid chromatography-tandem mass spectrometry analysis. Metabolomic analysis was performed using gas chromatography-mass spectrometry. The effect of the respective bariatric surgery on identified proteins and metabolites was evaluated using two-way analysis of variance and appropriate post-hoc tests.

resultsHOMA-IR improved, albeit not significantly, in both groups after surgery. Proteomic analysis yielded seven proteins which decreased significantly after GBP only, including Fetuin-A and Retinol binding protein 4, both previously linked to insulin resistance. Significant decrease in Fetuin-A and Retinol binding protein 4 after GBP was confirmed using ELISA and immunoassay. Metabolomic analysis identified significant decrease of citrate, proline, histidine and decanoic acid specifically after GBP.

conclusionGreater early decrease was seen for Fetuin-A, Retinol binding protein 4, and several metabolites after GBP compared to SG, preceding significant weight loss. This may contribute to enhanced T2D remission observed following foregut bypass procedures.

Indexed as

Adultalpha-2-HS-GlycoproteinDiabetes Mellitus, Type 2FemaleGastrectomyGastric BypassHumansInsulin ResistanceMaleMiddle AgedProspective StudiesProteomicsRetinol-Binding Proteins, PlasmaWeight LossAHSG protein, humanalpha-2-HS-GlycoproteinRBP4 protein, humanRetinol-Binding Proteins, Plasma

Identifiers

PMID24800810
PMCPMC4011803
OpenAlexW2061994471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.